IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v12y2021i1d10.1038_s41467-021-21159-7.html
   My bibliography  Save this article

Mutant-selective degradation by BRAF-targeting PROTACs

Author

Listed:
  • Shanique Alabi

    (Department of Pharmacology)

  • Saul Jaime-Figueroa

    (Molecular, Cellular, and Developmental Biology, Yale University)

  • Zhan Yao

    (Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center)

  • Yijun Gao

    (Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center)

  • John Hines

    (Molecular, Cellular, and Developmental Biology, Yale University)

  • Kusal T. G. Samarasinghe

    (Molecular, Cellular, and Developmental Biology, Yale University)

  • Lea Vogt

    (Molecular, Cellular, and Developmental Biology, Yale University)

  • Neal Rosen

    (Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center)

  • Craig M. Crews

    (Department of Pharmacology
    Molecular, Cellular, and Developmental Biology, Yale University
    Yale University)

Abstract

Over 300 BRAF missense mutations have been identified in patients, yet currently approved drugs target V600 mutants alone. Moreover, acquired resistance inevitably emerges, primarily due to RAF lesions that prevent inhibition of BRAF V600 with current treatments. Therefore, there is a need for new therapies that target other mechanisms of activated BRAF. In this study, we use the Proteolysis Targeting Chimera (PROTAC) technology, which promotes ubiquitination and degradation of neo-substrates, to address the limitations of BRAF inhibitor-based therapies. Using vemurafenib-based PROTACs, we achieve low nanomolar degradation of all classes of BRAF mutants, but spare degradation of WT RAF family members. Our lead PROTAC outperforms vemurafenib in inhibiting cancer cell growth and shows in vivo efficacy in a Class 2 BRAF xenograft model. Mechanistic studies reveal that BRAFWT is spared due to weak ternary complex formation in cells owing to its quiescent inactivated conformation, and activation of BRAFWT sensitizes it to degradation. This study highlights the degree of selectivity achievable with degradation-based approaches by targeting mutant BRAF-driven cancers while sparing BRAFWT, providing an anti-tumor drug modality that expands the therapeutic window.

Suggested Citation

  • Shanique Alabi & Saul Jaime-Figueroa & Zhan Yao & Yijun Gao & John Hines & Kusal T. G. Samarasinghe & Lea Vogt & Neal Rosen & Craig M. Crews, 2021. "Mutant-selective degradation by BRAF-targeting PROTACs," Nature Communications, Nature, vol. 12(1), pages 1-11, December.
  • Handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-21159-7
    DOI: 10.1038/s41467-021-21159-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-021-21159-7
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-021-21159-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Yuki Mori & Yoshino Akizuki & Rikuto Honda & Miyu Takao & Ayaka Tsuchimoto & Sota Hashimoto & Hiroaki Iio & Masakazu Kato & Ai Kaiho-Soma & Yasushi Saeki & Jun Hamazaki & Shigeo Murata & Toshikazu Ush, 2024. "Intrinsic signaling pathways modulate targeted protein degradation," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    2. Zefeng Wang & Shabnam Shaabani & Xiang Gao & Yuen Lam Dora Ng & Valeriia Sapozhnikova & Philipp Mertins & Jan Krönke & Alexander Dömling, 2023. "Direct-to-biology, automated, nano-scale synthesis, and phenotypic screening-enabled E3 ligase modulator discovery," Nature Communications, Nature, vol. 14(1), pages 1-12, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-21159-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.